


ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

2ND INTERNATIONAL WORKSHOP ON CANCER GENOMICS

CHARTING THE ROUTE FROM GENOMICS TO CLINICAL CARE: OPPORTUNITIES AND CHALLENGES FOR PRECISION CANCER MEDICINE AND PUBLIC HEALTH SYSTEMS



Rome, April 8-9, 2019

IRCCS Regina Elena National Cancer Institute

Multimedia Congress Center

Via Fermo Ognibene 23

2ND INTERNATIONAL WORKSHOP ON CANCER GENOMICS

CHARTING THE ROUTE FROM GENOMICS TO CLINICAL CARE: OPPORTUNITIES AND CHALLENGES FOR PRECISION CANCER MEDICINE AND PUBLIC HEALTH SYSTEMS

The advent of massive parallel DNA sequencing has made it possible to investigate the genomic abnormalities of cancer cells to an unprecedented level of complexity. This, in turn, has allowed genetically altered oncogenic drivers to be identified and exploited for therapeutic targeting in a sizeable fraction of human cancers. Persistent technological advancements have also made NGS implementation in the routine clinical pathology setting not only cost-effective, but also feasible. Finally, joint efforts by the academia and pharmaceutical industry have led to increasingly rapid development, clinical testing and eventual approval of a host of innovative, genomics-based, cancer therapeutics. Together, the above factors have ushered precision cancer medicine in routine clinical care, effectively producing a paradigm shift in clinical oncology. It must be recognized though that the successful clinical exploitation of cancer genomics still remains a challenging issue in a large fraction of tumor types, which, inevitably, conflicts with the ever increasing optimistic expectations of patients and physicians. This workshop will bring together an outstanding faculty of scientists and clinical oncologists, who work at the forefront of contemporary cancer research, with the aim to a) discuss some of the most pressing clinical and pre-clinical issues in genomics-oriented cancer research; b) present a realistic view regarding the scientific, financial and regulatory hurdles faced by the soon-to-be diffused implementation of precision cancer medicine.

PROGRAMME

Monday, April 8

14.00 Welcome address

Armando Bartolazzi (Sottosegretario Ministero della Salute)
Francesco Ripa di Meana (General Director IFO)
Gennaro Ciliberto (Scientific Director, IRCCS Regina Elena National Cancer Institute)

SESSION 1 Identification and targeting of tumor dependencies

(Chair: G. Melino and D. Barilà)

14.30 A data driven approach to nominate potential synthetic lethal partners

F. Demichelis (Center for Integrative Biology, University of Trento, Trento, Italy)

15.05 Cell autonomous and non-cell autonomous mechanisms of resistance

to targeted therapies

S. Giordano (Institute for Cancer Research and Treatment, Candiolo, Italy)

15.40 Patient-derived organoids: promises, hurdles and potential clinical application

N. Valeri (Division of Molecular Pathology, The Institute of Cancer Research, London, UK)

16.15	Coffee Break
16.40	Targeting unconventional epigenetically-regulated signaling pathways D. Hanahan (Swiss Institute of Cancer Research, Lausanne, Switzerland)
17.15	Molecular tumour boards as an instrument to implement precision medicine at the patient bedside M. Milella (Unit of Clinical Oncology, Department of Medicine, University of Verona, Italy)
Tuesd	ay, April 9
SESSION 2	Clinical implementation of precision cancer medicine Chair: F. De Braud and L. Del Mastro
9.15	The Drug Rediscovery Protocol (DRUP): using genomics to identify new opportunities for patients and approved drug E. Voest (Division of Molecular Oncology & Immunology, Nederland Cancer Institute, Amsterdam, The Nederlands)
9.50	Precision oncology therapeutic development: from BIG data to small trials A. Biankin (Institute of, Cancer Sciences, University of Glasgow, Glasgow, UK)
10.25	Applied Translational and Clinical Research: Re-engineering the Process for Access to Precision Oncology D. Lacombe (EORTC, Brussels, Belgium)
11.00	Molecular screening program in oncology A. Hollebecque (Drug Development Department, Gustave-Roussy CancerCampus Villejuif, France)
11.35	Coffee Break
12.00	Translating precision oncology into practice C. Von Kalle (German Cancer Research Center, Heidelberg, Germany)
12.35	Challenges in precision medicine trail design G. Curigliano (Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Milano, Italy)
13.10	Concluding Remarks and Farewell Address Gennaro Ciliberto (Scientific Director, IRCCS Regina Elena National Cancer Institute)

UNDER THE AUSPICIES OF











SCIENTIFIC COMMITTEE

ORGANIZATIONAL REFERENT

Gennaro Ciliberto

Tania Merlino

Rita Falcioni

Oreste Segatto

ORGANIZING SECRETARIAT



Scientific Organizing Service

SOS S.r.l. - Scientific Organizing Service Via Salaria, 237 - 00199 Roma Tel./Fax +39 06 854 06 79 - Mob. +39 333 659 35 41 rossella.spinetti@alice.it www.scientificorganizingservice.com